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Abstract
Background Delivering nicotine in the way smokers seek is
likely to be the key factor in e-cigarette (EC) success in re-
placing cigarettes. We examined to what degree different
types of EC mimic nicotine intake from cigarettes.
Methods Twelve participants (‘dual users’ of EC and ciga-
rettes) used their own brand cigarette and nine different EC
brands. Blood samples were taken at baseline and at 2-min
intervals for 10 min and again at 30 min.
Results Eleven smokers provided usable data. None of the EC
matched cigarettes in nicotine delivery (Cmax = 17.9 ng/ml,
Tmax = 4 min and AUC0–>30 = 315 ng/ml/min). The EC with
48 mg/ml nicotine generated the closest PK profile
(Cmax = 13.6 ng/ml, Tmax = 4 min, AUC0–>30 = 245 ng/ml/
min), followed by a third generation EC using 20 mg/ml nic-
otine (Cmax = 11.9 ng/ml, Tmax = 6 min, AUC0–>30 = 232 ng/
ml/min), followed by the tank system using 20mg/ml nicotine
(Cmax = 9.9 ng/ml, Tmax = 6 min, AUC0–>30 = 201 ng/ml/min).
Cig-a-like PK values were similar, ranging from Cmax 7.5 to
9.7 ng/ml, Tmax 4-6 min, and AUC0–>30 144 to 173 ng/ml/min.
Moderate differences in e-liquid nicotine concentrations had
little effect on nicotine delivery, e.g. the EC with 24 mg/ml
cartridge had the same PK profile as ECs with 16 mg/ml
cartridges. Using similar strength e-liquid, the tank EC pro-
vided significantly more nicotine than cig-a-like ECs.
Conclusions EC brands we tested do not deliver nicotine as
efficiently as cigarettes, but newer EC products deliver
nicotine more efficiently than cig-a-like brands. Moderate var-
iations in nicotine content of e-liquid have little effect on nic-
otine delivery. Smokers who are finding cig-a-like EC unsat-
isfactory should be advised to try more advanced systems.
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Introduction
Electronic cigarettes (EC) are a developing technology aiming
to provide nicotine without the harmful chemicals produced
by tobacco combustion (Etter 2012). EC have the potential to
generate a substantial public health benefit if there is a switch
from smoking to EC use on a population scale (Public Health
England 2015; RCoP 2016). So far, however, only a minority
of smokers who try EC progress to the full switch from
smoking to vaping (Douptcheva et al. 2013; Kralikova et al.
2013; Farsalinos et al. 2016). This suggests that the currently
available EC products do not yet match combustible tobacco
closely enough in providing smokers with what they want
from their cigarettes. The nicotine delivery profile is likely to
play a major role (Caldwell et al. 2012; McRobbie et al. 2010).
The parameters of nicotine delivery that are likely to be
important for smokers include the overall nicotine dose and
the speed of nicotine absorption (Schroeder and Hoffman
2014). Several studies compared nicotine yields from ciga-
rettes and from EC using puffing machines (Cobb et al.
2010; Farsalinos et al. 2013; Goniewicz et al. 2014;
Goniewicz et al. 2013; McAuley et al. 2012; Pellegrino et al.
2012; Trehy et al. 2011; Westenberger 2009). Earlier EC were
shown to deliver much less nicotine than cigarettes, but recent
devices used at high power setting have improved nicotine
delivery (Farsalinos et al. 2016). Machine yields, however,
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may not correspond with the actual delivery of nicotine into
the blood stream of users and the method provides no infor-
mation about the speed with which nicotine is absorbed. Some
studies measured levels of cotinine, a metabolite of nicotine,
in vapers, but this is more difficult to interpret because it is not
known what proportion of cotinine is derived from nicotine
that has been swallowed; and cotinine levels also provide no
data on speed of nicotine delivery.
Some data comparing nicotine concentrations in blood
samples from smokers and vapers exist as well. In smokers
with no experience of EC use, first generation ‘cig-a-like’ EC
delivered nicotine very slowly and at low concentrations
(Bullen et al. 2010; Vansickel and Eissenberg 2012a;
Vansickel et al. 2012b) suggesting buccal rather than pulmo-
nary absorption. There is some evidence that experience with
EC improves nicotine intake (Hajek et al. 2014) and so studies
with experienced vapers using their EC ad-lib are probably
more informative. In a study with experienced vapers who
were, however, still prescribed a puffing schedule, nicotine
concentrations reached 7 ng/ml 10 min after a 10-puff bout
(Dawkins and Corcoran 2014). For comparison, plasma nico-
tine concentrations from a single cigarette average 15–
20 ng/ml (Benowitz et al. 2006). Ad-lib vaping for an hour
generated nicotine concentrations of up to 14 ng/ml in one
study (Dawkins and Corcoran 2014) and 16 ng/ml in another
(Vansickel and Eissenberg 2012a). In smokers with no expe-
rience with EC and a fairly intensive puffing schedule pre-
scribed, 5 min after initiation, venous blood nicotine levels
achieved with 8, 18 and 36 mg liquid were 9, 13 and 17 ng/ml
(Lopez et al. 2015) while in an identical experiment with
experienced vapers, the levels were 18, 26 and 36 ng/ml
(Ramôa et al. 2015).
Apart from user experience and puffing characteristics, the
type of EC is likely to play a major role. More advanced
refillable EC products with stronger batteries delivered nico-
tine more efficiently than a ‘cig-a-like’ EC in one study
(Farsalinos et al. 2014). Cigarettes typically reach time of
maximal nicotine concentration (Tmax) within a few minutes
(Digard et al. 2013) while early first-generation EC achieved
Tmax after 20 min (Bullen et al. 2010). Experienced vapers
using their own EC, mostly tank systems, though again with
a prescribed puffing schedule, averaged maximum plasma
nicotine concentration (Cmax) of only 8 ng/ml, but the Tmax
was 5 min (St Helen et al. 2015). Even higher levels were
achieved in a recent study where experienced vapers used an
advanced vaping device with 24 mg/ml e-liquid (44 ng/ml
after 1 h) (Dawkins et al. 2016).
Up to now, little is known about differences in nicotine
delivery between individual EC brands. Among nicotine re-
placement treatments, those that deliver nicotine faster are more
likely to be used long-term (Hajek et al. 2007; Sutherland et al.
1992). It is likely that compared to EC with low and slow
nicotine delivery, devices with a faster and higher nicotine
delivery will appeal to smokers more and will have a better
potential to replace cigarettes and assist with smoking cessa-
tion. Other EC characteristics such as taste, ease of use, puff
resistance, vapour volume and handling characteristics (and of
course cost, as well as product marketing) are likely to be
important too, but it can be expected that the nicotine delivery
profile will be paramount. One sign of this is that nicotine
containing EC dominate the market with nicotine-free models
hardly used despite being otherwise equivalent and widely
available (Etter 2012). Nicotine delivery, however, may need
to fit into a relatively narrow range at both ends. Very high
nicotine concentration liquids are also rarely used.
EC technology is evolving and market forces are likely to
steer product development to features that appeal to smokers
and increase the rate of adoption, but the process could be
slow. Data are needed that monitor pharmacokinetic (PK)
characteristics of different EC brands to provide information
that could guide smokers faced with the wide range of differ-
ent EC products, inform the choice of EC brands for studies of
the potential of EC in smoking cessation, and guide further
product development.
In the first study of this type, we tested PK profiles of eight
common EC brands, together with conventional cigarettes and
with vapers’ own devices. We also adjusted the common meth-
odology in this field to our particular aim. Most studies
assessing nicotine intake from alternative nicotine delivery
products take the first post-baseline sample 5 min after the
initial nicotine intake. We started 2 min after the first puff and
followed the changes in nicotine absorption in 2-min intervals
to allow for more accurate comparison with smoking and to
assess whether speed of nicotine absorption suggest a buccal or
a much faster pulmonary route. We also asked experienced
vapers to use each device after overnight abstinence ad lib.
EC studies up to now have typically used prescribed puffing
schedules that do not allow for individual adjustments smokers
make when using different products and may not correspond to
‘real-life’ levels of nicotine that vapers obtain from vaping.
Methods
Aim and design
A crossover study to establish PK profiles of eight popular EC
products and participants’ own EC and to compare them with
the PK profile obtained from their own cigarettes; and to as-
sess effects on PK profiles of different e-liquid strengths and
different types of EC models.
Participants
Twelve healthy smokers who were currently smoking and
vaping (‘dual users’) and who were willing to test a series of
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EC products were recruited via UK on-line forums of EC
users and by word of mouth.
Study procedures and setting
Participants were pre-screened over the telephone and
attended the laboratory after overnight abstinence from both
smoking and vaping.
At the first session, participants smoked a cigarette of their
usual brand that they brought with them. At the next session,
own-brand EC was tested, followed by eight EC brands, al-
ways tested in the same order. Sessions were scheduled with at
least 3-day ‘wash out’ periods between them.
The sessions took place between 7.30 and 9.30 am, depend-
ing on the participants’ availability, and took about 60 min.
Participants received £60 at the end of each session.
At each session, an intravenous line for blood sampling
was placed in the forearm and the baseline blood sample
was taken, after which participants were asked to smoke/
vape ad-lib for 5 min. Further blood samples were taken at
2, 4, 6, 8, 10 and 30 min after starting smoking/vaping.
Measures
Demographic and smoking history data were collected at
baseline. Subjective product ratings were collected at the end
of each session. (This report focuses on nicotine delivery from
different types of EC compared to nicotine delivery from cig-
arettes. Other product characteristics and user ratings from a
larger sample that included participants who did not smoke
anymore and so did not provide data on nicotine delivery from
their cigarette will be covered separately.)
Blood samples were analysed at ABS Laboratories Ltd.,
BioPark, Broadwater Road, Welwyn Garden City,
Hertfordshire, UK. During the 5 min of ad-lib smoking and
vaping, investigators kept count of the number of puffs taken.
Study products
We chose a range of popular first generation products, includ-
ing all those marketed by major tobacco companies, and ex-
amples of the second and third generation EC. The following
six first generation (cig-a-like) products were tested: Gamucci
(16 mg/ml nicotine, ‘original taste’ (tobacco)), Blu (18 mg/ml
nicotine, ‘classic tobacco’), Vype (16.8 mg/ml, ‘classic tobac-
co flavour’, regular), E-lites (24 mg/ml nicotine, ‘original’
(tobacco)), Puritane (20 mg/ml, ‘original’ (tobacco)) and
Vuse (4.8% nicotine (i.e. 48 mg/ml), ‘original’ (tobacco)).
The cig-a-like products included the five EC marketed by
the tobacco industry (Blu—Imperial Tobacco, Vype—British
American Tobacco, Puritane—Imperial Tobacco, E-lites—
Japan Tobacco and Vuse—RJ Reynolds), and one product
produced by an independent manufacturer and popular in
the UK (Gamucci). Using E-lites also allowed testing of a
product available with cartridges that have a higher nicotine
concentration (24 mg/ml).
We also tested one second generation refillable ‘tank’ prod-
uct, a popular mid-range KangerTech EVOD, and one third
generation product (a tank product which allows variable
power setting), Innokin iTaste MVP 2 with an ‘iClear’ atom-
izer (2.1Ohm), set to 11 W. Both of these refillable products
were used with the same 20 mg/ml nicotine e-liquid
(Vermillion River ‘classic blend’ (tobacco)).
For products marketed at different strengths, nicotine con-
centrations were selected to be as close as possible to 20 mg/
ml. Across products tested, the e-liquids contained 16–20 mg/
ml of nicotine, with two exceptions. We used E-lites with
24 mg/ml of nicotine to assess a cig-a-like product with a
higher nicotine content; and Vuse was only available with
strength marked as 4.8%, translating into 48 mg/ml. Table 1
provides product details.
Regarding the own brand EC, participants used the follow-
ing first generation products: Vapestick disposable (18 mg/ml,
original), 10 motives (16 mg/ml menthol and 2 × 16 mg/ml,
regular) and Vapourlites (11 mg/ml, cherry). The following
second generation products were used: KangerTech EVOD
(12 mg/ml, menthol - Dekang), Aspire CF G Power battery
with BDC cartomiser (9 mg/ml, American tobacco –
FLAVaah!), iBaccy (24mg/ml, chocolate - VIP). The following
third generation products were used: E-lectron-S (18 mg/ml,
cherry -Totally Wicked), Eleaf iStick subtank (6 mg/ml, fruit
punch – Mystic Juice), Aspire nautilus (12 mg/ml sweet pru-
dence - Halcyon Haze), Torchwood battery with atomic atom-
iser (12 mg/ml vanilla custard – own mix).
Statistical analyses
PK parameters were calculated using PKSolver add-in for
Excel (V2.0 (Zhang et al. 2010)). The following PK parame-
ters were calculated: (1) time at which the highest nicotine
concentration occurred in plasma (Tmax); (2) the highest drug
concentration observed in plasma (Cmax); (3) estimated area
under the plasma nicotine curve concentration from time 0 to
30 min (AUC0–>30). All measures were corrected for baseline
values. Cmax, Tmax and AUC0–>30 were estimated using a non-
compartmental model and trapezoidal rule. Differences be-
tween products were analysed using paired-sample t test.
Analyses were performed with SPSS v.22.
Results
One participant dropped out within the first 5 weeks. The
analyses below include the remaining 11 participants.
Table 2 provides baseline characteristics of the sample.
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PK profiles achieved with individual EC products and with
own brand cigarettes are shown in Fig. 1.
Table 3 provides PK parameters for each product. None of
the products matched cigarettes in terms of nicotine delivery
despite the fact that the participants took significantly more
puffs from most of them.
Among the eight EC products tested, Vuse which used an
exceptionally high nicotine concentration e-liquid (48 ng/ml)
generated the most efficient nicotine absorption, followed by
the third generation EC device Innokin using 20 mg/ml nico-
tine e-liquid, followed by the second generation EC device
Kanger using the same e-liquid.
Small differences in e-liquid nicotine concentrations in cig-
a-like brands had no bearing on nicotine delivery, e.g. E-lites
using 24 mg/ml cartridges had a virtually identical PK profile
to Gamucci and Vype with 16 mg/ml nicotine concentrations.
Participants took a greater number puffs when using EC
compared to cigarettes; the differences were significant for all
EC products except the two refillables (KangerTech and
Innokin) and the 24 ml/mg E-lites.
Table 4 shows PK parameters of the five cig-a-like prod-
ucts other than Vuse (Blu, Puritane, Vype, Gamucci and E-
lites and the two refillable products (KangerTech and
Innokin). Refillable EC produced significantly higher Cmax
and AUC0–>30.
Discussion
The main findings of this study provide a new insight into EC
products when used by experienced vapers ad-lib. EC brands
we tested deliver less nicotine than cigarettes and do it more
slowly despite users taking significantly more puffs than when
using cigarettes. The maximum nicotine concentrations of un-
der 10 ng/ml achieved only after some 6 min suggest that
nicotine may have been delivered largely via buccal rather
than pulmonary absorption. However, Vuse, an EC with a
very high nicotine content, and the third generation EC we
tested at a high power setting, are beginning to catch up with
cigarettes. With the exception of Vuse, different cig-a-like
products produced by different manufacturers may differ in
appearance and various other characteristics, but in terms of
nicotine delivery, they are practically identical. Refillable EC
brands using similar strength of e-liquid delivered nicotine
significantly more efficiently.
The main limitation of the study is the small sample size.
Individual participants differed in their nicotine intake from
different products and the results may have been influenced
by ‘outlier’ values. Another limitation is that although the par-
ticipants were experienced vapers, they had no prior experience
with the products tested. This means that they may have not
used the tested EC in an optimal way or in a way they would
use them if they were familiar with them. Superficial charac-
teristics such as product flavour or draw resistance may have
influenced product use and therefore nicotine intake. The re-
sults could have been different after a period of familiarisation
with each product. We also did not verify nicotine content of
ECwe used, but our previous study suggested that the labelling
of popular EC products is reasonably precise (Goniewicz et al.
Table 1 Summary of EC
products tested Brand and manufacturer Nicotine content per ml
as per packaging
Starter pack and cartridge
or e-liquid price
Gamucci (Gamucci XL Distributors Inc.) 16 mg £9.99/ £2.33 per cartridge
Blu (Imperial Tobacco) 18 mg £14.99/ £2 per cartridge
Vype (British American Tobacco) 16.8 mg £14.99/ £2 per cartridge
E-lites Original Instant Use (Japan Tobacco) 24 mg £6.49/ £3.49 per cartridge
Puritane (Imperial Tobacco) 20 mg £22.99/ £4.50 per cartridge
Vuse (RJ Reynolds) 48 mg £6.25/ £1.90 per cartridge
KangerTech EVOD (Kanger Technology) 20 mg £32/ £4.99 per 10 ml e-liquid
Innokin itaste MVP 2, 4.8v (Innokin Technology) 20 mg £34/ £4.99 per 10 ml e-liquid
Table 2 Baseline characteristics (N = 11)
Age, mean (SD) 34.1 (12.0)
Male (%) 91
Higher education (%) 73
Cigarettes smoked per day before starting EC
use, mean (SD)
12.4 (8.4)
Fagerstrom Test for Nicotine Dependence
(FTND) before EC use, mean (SD)
3.4 (2.5)
EC cartridges used per day, mean (SD)a 1.5 (1.5)
Millilitres of e-liquid used per day, mean (SD)b 3.3 (1.1)
No. months using EC daily, mean (SD) 15.7 (16.2)
Days EC used in last week, mean (SD) 7 (0)
Cigarettes smoked per day currently, mean (SD)c 1.6 (2.0)
aN = 5
bN = 6
c Calculated by dividing the answer to the question about cigarettes
smoked per week by 7
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2014). Finally, because obtaining regulatory approvals for any
study with human subjects takes many months and trial com-
pletion and publication takes time as well, publications in this
area of fast technological developments will never report on the
newest EC models. The most recent EC products are likely to
provide better nicotine delivery than the products we tested.
Within these limitations, the key results seem fairly robust.
EC products that we tested do not yetmatch cigarettes in nicotine
delivery profile. The developmental trajectory, however, seems
to be moving to EC products that deliver nicotine faster. Second
and third generation EC deliver nicotine more effectively than
‘cig-a-likes’. One EC that was an outlier is Vuse, a ‘hybrid’
product that uses a large cartridge and a much stronger e-liquid.
Smokers typically start with cig-a-like EC but those who
switch completely to EC are more likely to use tank systems
(ASH 2015). Our results suggest that this is in part at least linked
to their better nicotine delivery. It is of interest to note that five of
the study participants used cig-a-like products and almost all
used weak or ‘mild’ e-liquids. This may be because they did
not discover better products yet and that could also be the reason
that they remained dual users rather than switching to vaping
altogether, but the observation could also reflect the fact that
the participants were on average relatively light smokers before
they started to vape. While EC with better nicotine delivery are
likely to be more helpful for heavy smokers, it is important to
note that not all smokers seek high nicotine concentrations. It is
also highly likely that other chemicals in tobacco smoke apart
from nicotine contribute to the attractiveness of smoking. Unlike
cigarettes that satisfy smokers and encourage non-smokers to
start regular use, nicotine on its own, e.g. in NRT products
and, up to now, in EC, has limited appeal to smokers
(Kralikova et al. 2013) and no appeal to non-smokers (ASH
2015; Brown et al. 2014; Gerlach et al. 2008).
There are large differences between individual vapers in
their requirement for nicotine and in what they want from


























Fig. 1 Pharmacokinetic profiles
of own brand cigarette and each
electronic cigarette product
Table 3 Nicotine delivery and
number of puffs from own brand
cigarette, own brand EC and eight
EC products
Product Mean no. of
puffs (SD)
Mean Cmax (SD) Mean Tmax (range) Mean AUC0–>30 (SD)
Cigarette 14 (4.5) 17.9 (16.0) 4 (2–30) 314.6 (155.1.)
Vuse 19 (5.1)* 13.6 (9.7) 4 (2–10) 244.9 (116.1)
Innokin 17 (5.2) 11.9 (7.0) 6 (4–30) 232.1 (112.5)
KangerTech EVOD 18 (5.9) 9.9 (6.6) 6 (6–30) 200.6 (120.1.)
Gamucci 18 (5.4)* 9.7 (4.4) 6 (2–10) 169.9* (74.9)
Own Brand EC 18 (5.3)* 9.5 (6.1) 6 (2–30) 186.4* (96.6)
Blu 20 (6.4)* 9.1 (6.8) 6 4–30 173.1* (112.4)
Vype 22 (7.1)* 8.5 (5.7) 6 4–30) 161.0* (98.6)
E-lites 17 (5.1) 7.8 (4.6) 6 (4–30) 157.6* (69.9)
Puritane 22 (11.4)* 7.5 (5.0) 4 (4–10) 144.4* (67.2)
Tmax and AUC values that were used to compare EC products statistically used means across individuals while
values shown in Fig. 1 and Table 3 estimated by PK Solver used means across time points
*Significant difference compared to cigarette (P ≤ 0.05)
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concentrations obtained from their own EC. Availability of a
range of different EC products is likely to increase the likeli-
hood that smokers find an EC that fits their needs.
In terms of practical implications of our findings, heavy
smokers who are finding cig-a-like EC unsatisfactory should
be advised to try tank products or a cartridge EC with a high
nicotine concentration. Smoking cessation trials seeking to
evaluate ECwith the best treatment potential should offer tank
EC with a choice of liquid strengths. Manufacturers should be
encouraged to continue developing products that provide
smokers with what they seek from their cigarettes while main-
taining maximum product safety.
In conclusion, EC products that we tested do not deliver
nicotine as efficiently as cigarettes, but refillable EC deliver
nicotine more efficiently than cig-a-like products. Moderate
variations in nicotine content of e-liquid have little effect on
nicotine delivery. Smokers who are finding cig-a-like EC un-
satisfactory should be advised to try more advanced systems,
as should studies seeking to evaluate EC treatment potential.
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